Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-26-023210
Filing Date
2026-05-14
Accepted
2026-05-14 17:30:07
Documents
72
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 2572804
2 EX-31.1 ex31-1.htm EX-31.1 31821
3 EX-32.1 ex32-1.htm EX-32.1 13936
  Complete submission text file 0001493152-26-023210.txt   11714317

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ppcb-20260331.xsd EX-101.SCH 69615
5 XBRL CALCULATION FILE ppcb-20260331_cal.xml EX-101.CAL 75463
6 XBRL DEFINITION FILE ppcb-20260331_def.xml EX-101.DEF 358664
7 XBRL LABEL FILE ppcb-20260331_lab.xml EX-101.LAB 574936
8 XBRL PRESENTATION FILE ppcb-20260331_pre.xml EX-101.PRE 472352
75 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1671484
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-42806 | Film No.: 26980669
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)